UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers

Cancer science, 2021-10, Vol.112 (10), p.4393-4403

2021

Volltextzugriff (PDF)

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1114-1122

2021

Volltextzugriff (PDF)

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Scientific reports, 2021-09, Vol.11 (1), p.18762-18762, Article 18762

2021

Volltextzugriff (PDF)

Toward Efficient Synthesis of Chiral Zeolites: A Rational Strategy for Fluoride‐Free Synthesis of STW‐Type Zeolite

Angewandte Chemie International Edition, 2020-11, Vol.59 (45), p.20099-20103

International ed. in English, 2020

Volltextzugriff (PDF)

Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single‐cell level

Cancer science, 2021-05, Vol.112 (5), p.2006-2019

2021

Volltextzugriff (PDF)

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

Cancer Immunology, Immunotherapy, 2022-02, Vol.71 (2), p.387-398

2022

Volltextzugriff (PDF)

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Journal of thoracic oncology, 2021-12, Vol.16 (12), p.2078-2090

2021

Volltextzugriff (PDF)

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Journal of cancer research and clinical oncology, 2021, Vol.147 (1), p.245-251

2021

Volltextzugriff (PDF)

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

Cancer Immunology, Immunotherapy, 2022-03, Vol.71 (3), p.737-746

2022

Volltextzugriff (PDF)

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Lung cancer (Amsterdam, Netherlands), 2022-11, Vol.173, p.35-42

2022

Volltextzugriff (PDF)

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

Clinical lung cancer, 2022-07, Vol.23 (5), p.386-392

2022

Volltextzugriff (PDF)

Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

British journal of cancer, 2021-03, Vol.124 (5), p.925-932

2021

Volltextzugriff (PDF)

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight

Cancer science, 2023-05, Vol.114 (5), p.2087-2097

2023

Volltextzugriff (PDF)

P37-1 Liquid biopsy for the detection of the resistant mutation to ROS1 and RET inhibitors: A case series study

Annals of oncology, 2022-07, Vol.33, p.S528

2022

Volltextzugriff (PDF)

Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer

Cancer Immunology, Immunotherapy, 2020-07, Vol.69 (7), p.1229-1236

2020

Volltextzugriff (PDF)

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

Anticancer research, 2021-11, Vol.41 (11), p.5739-5747

2021

Volltextzugriff (PDF)

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients

Clinical lung cancer, 2022-09, Vol.23 (6), p.477-486

2022

Volltextzugriff (PDF)

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy

Lung cancer (Amsterdam, Netherlands), 2023-05, Vol.179, p.107183-107183, Article 107183

2023

Volltextzugriff (PDF)

Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer

Medical oncology (Northwood, London, England), 2020-03, Vol.37 (4), p.30-30, Article 30

2020

Volltextzugriff (PDF)

Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant

European journal of clinical pharmacology, 2022-04, Vol.78 (4), p.613-621

2022

Volltextzugriff (PDF)

Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.9044-9044

2021

Volltextzugriff (PDF)

Corrigendum to: Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Japanese journal of clinical oncology, 2021-07, Vol.51 (7), p.1183-1183

2021

Volltextzugriff (PDF)

Old age and underlying interstitial abnormalities are risk factors for development of ARDS after pleurodesis using limited amount of large particle size talc

Respirology (Carlton, Vic.), 2018-01, Vol.23 (1), p.55-59

2018

Volltextzugriff (PDF)

Performance of Japanese patients in registrational studies

Japanese journal of clinical oncology, 2022-01, Vol.52 (1), p.53-64

2022

Volltextzugriff (PDF)

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy

Cancers, 2023-08, Vol.15 (16), p.4018

2023

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(89)
Mit Volltextzugriff
(99)

Publikationsform

Artikel
(100)
Berichte
(2)

Sprache

Englisch
(94)
Japanisch
(27)

Erscheinungsjahr

n.n

Thema

Science & Technology
(55)
Life Sciences & Biomedicine
(52)
Oncology
(45)
Humans
(35)
Lung Cancer
(28)
Lung Neoplasms - Drug Therapy
(22)
Respiratory System
(21)
Retrospective Studies
(20)
Aged
(17)
Patients
(17)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(16)
Male
(16)
Non-Small Cell Lung Cancer
(16)
Female
(15)
Non-Small Cell Lung Carcinoma
(15)
Original
(15)
Adult
(14)
Middle Aged
(14)
Small Cell Lung Carcinoma
(14)
Aged, 80 And Over
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Clinical characteristics of advanced non-small cell lung cancer patients with EGFR exon 20 insertions

Toward Efficient Synthesis of Chiral Zeolites: A Rational Strategy for Fluoride‐Free Synthesis of STW‐Type Zeolite

Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single‐cell level

Prognostic significance of cachexia in advanced non-small cell lung cancer patients treated with pembrolizumab

Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC

Efficacy of anti-PD-1 antibodies in NSCLC patients with an EGFR mutation and high PD-L1 expression

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: a consecutive analysis of patients having NSCLC with high PD-L1 expression

Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients

Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Deficient Thoracic Tumor

Prognostic impact of peripheral blood neutrophil to lymphocyte ratio in advanced-stage pulmonary large cell neuroendocrine carcinoma and its association with the immune-related tumour microenvironment

Pharmacokinetic and dose‐finding study of osimertinib in patients with impaired renal function and low body weight

P37-1 Liquid biopsy for the detection of the resistant mutation to ROS1 and RET inhibitors: A case series study

Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer

Smoking History Predicts High Presence of TILs and Efficacy of PD-1 Blockade in PD-L1 Expression-negative Non-small Cell Lung Cancer Patients

Concurrent High PD-L1 Expression and CD8+ Immune Cell Infiltration Predict PD-1 Blockade Efficacy in Advanced EGFR-Mutant NSCLC Patients

Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy

Clinical characteristics of adrenal insufficiency as an immune-related adverse event in non-small-cell lung cancer

Evaluation of hepatic CYP3A enzyme activity using endogenous markers in lung cancer patients treated with cisplatin, dexamethasone, and aprepitant

Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients

Corrigendum to: Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients

Old age and underlying interstitial abnormalities are risk factors for development of ARDS after pleurodesis using limited amount of large particle size talc

Performance of Japanese patients in registrational studies

Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy

Suchergebnisse filtern